Presenters
General Practitioner (GP)
Dr. Sarah Jarvis
Professor of Medicine and Cardiology
Professor Nikolaus Marx
Adjunct Professor, Department of Diabetes
Professor Per-Henrik Groop
Course Details
The aim of this webinar is to provide updates on the 10 years of Efficacy data, Cardiovascular & Renal Safety data and Convenience of Linagliptin and how it supports the Simplicity of its use for a broad range of Type 2 Diabetes patients.
CPD Points: 1.5 Points
PRC Program No: PROG-2021-21424
10 Years of Simplicity in T2D Management Course Outline
- Robust CV and kidney safety data from CARMELINA® and CAROLINA® in patients across a broad spectrum of T2D disease duration, CV and kidney risk. Trajenta® is the only DPP4i with 2 large CVOTs, including an active-comparator trial
- A Broad Range of T2D Patients Can Benefit From The Simplicity of Linagliptin
- Patient cases incorporating speaker experience with Linagliptin (Trajenta®)
- Data from Linagliptin (Trajenta®) CVOTs support treatment decision making
- Summarising The Advances That Linagliptin Has Brought to T2D Care
- Course Evaluation